| Literature DB >> 25706956 |
Jianwu Bai1, Steven L Smock1, George R Jackson2, Kenzie D MacIsaac1, Yongsheng Huang1, Courtney Mankus2, Jonathan Oldach2, Brian Roberts1, Yu-Lu Ma1, Joel A Klappenbach1, Michael A Crackower1, Stephen E Alves1, Patrick J Hayden2.
Abstract
OBJECTIVES: Human airway epithelial cells are the principal target of human rhinovirus (HRV), a common cold pathogen that triggers the majority of asthma exacerbations. The objectives of this study were 1) to evaluate an in vitro air liquid interface cultured human airway epithelial cell model for HRV infection, and 2) to identify gene expression patterns associated with asthma intrinsically and/or after HRV infection using this model.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25706956 PMCID: PMC4338293 DOI: 10.1371/journal.pone.0118286
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Donor information.
| Donor # | Asthma | Gender | Age | Race | Smoking | Height (inches) | Weight (Pounds) | Other Disease | Medications |
|---|---|---|---|---|---|---|---|---|---|
| 11 | No | F | 38 | C | Yes. 16 PY | 65 | 106 | ||
| 12 | Yes | F | 59 | H | No | 60 | 194 | COPD, D, HTN | Advair |
| 14 | Yes | F | 46 | C | Yes. 30 PY | 69 | 305 | D | |
| 15 | Yes | F | 45 | C | Yes. 30 PY | 62 | 165 | COPD, D, HTN, G | Albuterol, Advair |
| 18 | Yes | F | 64 | C | No | 65 | 189 | COPD, D, HTN | Advair, Albuterol |
| 20 | No | M | 13 | C | No | 73 | 220 | ||
| 21 | No | F | 62 | B | No | 66 | 207 | ||
| 22 | No | M | 35 | C | No | 68 | 205 | HTN | Copazine, benadryl, lisinopril, darvocet |
| 23 | No | M | 52 | C | Yes. 20PY | 69 | 167 | ||
| 26 | Yes | F | 9 | B | No | 52 | 88 | Albuterol, Advair | |
| 28 | Yes | F | 55 | C | Yes. Light | 65 | 258 | D, HTN | Prednisone, Albuterol inhaler, others |
| 30 | No | M | 50 | H | No | 72 | 216 |
Abbreviations: F, Female; M, Male; C, Caucasian; H, Hispanic; B, Black; PY, Pack-Year, D; Diabetes, HTN; Hypertension, G; Glaucoma
Fig 1Time course of RV-A16 infection for asthmatic (n = 6) and non-asthmatic (n = 6) donor groups (A) and each donor (B) in ALI cultures.
Viral genome levels in cell lysates were measured by qPCR at three time points, and were presented as viral RNA copies /culture. There was no significant difference in the mean viral genome levels between asthmatic and non-asthmatic samples. The p values between asthma and non-asthmatic samples are 0.48, 0.53 and 0.13 at 1.5, 8, and 24 hours post exposure (p.e.) respectively.
Fig 2ALI cultured HAECs were infectible by RV-A16.
Immunofluorescence micrographs of transverse sections of ALI cultures shows RV-A16 replicated in ALI cultured HAECs. Positive immunofluorescence staining for mabj2 (in green) was not observed in uninfected control tissues (top panel), but was observed in RV-A16 infected tissues (bottom panel); DAPI staining in blue shows cell nuclei in the tissues. Scale bars: 50 μm.
Fig 3Functional pathways that showed statistically significant differential expression between RV-A16 and Vehicle groups (p<0.05).
Outliner is shown individually with a solid circle.
Fig 4Distributions of differentially expressed genes in asthmatic samples after treatment of vehicle or RV-A16.
579 genes in the “Asthma vs. non-asthma at baseline” group had baseline difference between asthmatic and non-asthmatic cells (p<0.05); 497 genes in the “Asthma vs. non-asthma after HRV infection” group had asthma-related viral response (p<0.05); and 1485 genes in the “HRV response group had strong expression changes associated with viral infection across both asthma and non-asthma donors. The numbers of genes only in one group or common for either two or three groups are shown by either exclusive or overlapping areas in Venn diagrams. The diagrams were generated with an online tool available at http://bioinfogp.cnb.csic.es/tools/venny/.
Differentially expressed genes between asthma and non-asthma groups both at baseline and after HRV 16 infection.
| Gene Symbol | Gene name | Biological function | Base line difference p-value | Differential viral response (As vs. non-As) | Viral infection correlation p-value | |
|---|---|---|---|---|---|---|
| Fold Change | p-value | |||||
| CCRL1 | chemokine (C-C motif) receptor-like 1 | decoy chemokine receptor | 0.002 | 1.686 | 0.049 | 4.1E-06 |
| LRIG1 | Leucine-rich repeats and immunoglobulin-like domains protein 1 | protein binding | 0.004 | 0.528 | 0.016 | 2.8E-07 |
| ERBB4 | v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian) | a receptor tyrosine kinase | 0.009 | 1.358 | 0.037 | 2.6E-07 |
| RNF44 | ring finger protein 44 | protein binding | 0.009 | 0.701 | 0.044 | 2.7E-06 |
| STARD4 | StAR-related lipid transfer (START) domain containing | lipid transport | 0.015 | 1.857 | 0.013 | 6.6E-10 |
| CCL5 | chemokine (C-C motif) ligand 5 | chemokine | 0.026 | 1.857 | 0.047 | 2.6E-14 |
| LOC388692 | hypothetical LOC388692 | NA | 0.026 | 1.432 | 0.043 | 7.4E-07 |
| KLHDC3 | kelch domain containing 3 | protein binding | 0.041 | 0.581 | 0.028 | 2.1E-06 |
Differentially expressed genes between asthma and non-asthma groups after HRV 16 infection.
| Gene Symbol | Gene name | Biological function | Differential viral response (As vs. non-As) | Viral infection correlation p-value | |
|---|---|---|---|---|---|
| Fold change | p-value | ||||
| CXCL10 | chemokine (C-X-C motif) ligand 10 | chemokine | 3.353 | 0.005 | 9.5E-15 |
| ZBP1 | Z-DNA binding protein 1 | DNA binding | 1.522 | 0.050 | 2.9E-15 |
| C19orf66 | chromosome 19 open reading frame 66 | NA | 1.402 | 0.046 | 1.2E-14 |
| GBP5 | guanylate binding protein 5 | Guanylate binding protein | 1.634 | 0.035 | 9.5E-13 |
| NUB1 | negative regulator of ubiquitin-like proteins 1 | protein binding | 1.548 | 0.030 | 1.3E-12 |
| C1orf38 | chromosome 1 open reading frame 38 | NA | 1.891 | 0.012 | 7.1E-12 |
| TICAM1 | toll-like receptor adaptor molecule 1 | protein binding, anti-viral defense, apoptosis | 1.477 | 0.043 | 6.5E-12 |
| APOBEC3F | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F | protein binding, RNA binding, anti-viral defense | 1.558 | 0.035 | 4.1E-10 |
| BCL7A | B-cell CLL/lymphoma 7A | negative regulation of transcription | 0.513 | 0.017 | 6.9E-08 |
| FAM104B | family with sequence similarity 104, member B | NA | 0.592 | 0.049 | 3.0E-08 |
| CCDC109B | coiled-coil domain containing 109B | ion channel activity | 1.844 | 0.043 | 2.1E-07 |
| PARP8 | ubiquitin specific peptidase 15 | NA | 1.556 | 0.021 | 7.0E-08 |
| GCLC | glutamate-cysteine ligase, catalytic subunit | glutamate cystein ligase activity | 0.654 | 0.022 | 1.4E-06 |
| FAM60A | family with sequence similarity 60, member A | protein binding | 0.624 | 0.007 | 8.4E-08 |
| KCNQ4 | potassium voltage-gated channel, KQT-like subfamily, member 4 | ion channel activity | 2.106 | 0.026 | 2.1E-06 |
| VGLL4 | vestigial like 4 (Drosophila) | transcription | 0.701 | 0.032 | 1.3E-07 |
| GOLPH3L | golgi phosphoprotein 3-like | protein binding | 0.681 | 0.037 | 2.2E-06 |
| LIMS1 | LIM and senescent cell antigen-like domains 1 | protein binding | 0.543 | 0.004 | 1.1E-06 |
| USP15 | ubiquitin specific peptidase 15 | enzyme activity | 1.453 | 0.035 | 1.2E-06 |
| PEX6 | peroxisomal biogenesis factor 6 | protein binding | 0.555 | 0.045 | 4.9E-06 |
| FHOD1 | formin homology 2 domain containing 1 | protein binding, actin binding | 0.592 | 0.044 | 6.0E-06 |
| FXR1 | fragile X mental retardation, autosomal homolog 1 | RNA binding | 0.709 | 0.020 | 1.2E-06 |
| IARS2 | isoleucyl-tRNA synthetase 2, mitochondrial | ATP binding, aminoacyl -tRNA editing activity | 0.708 | 0.016 | 2.7E-06 |
| PTPLAD2 | protein tyrosine phosphatase-like A domain containing 2 | lysase activity | 0.426 | 0.010 | 6.1E-05 |
| SLC23A2 | solute carrier family 23 (nucleobase transporters), member 2 | nucleobase transporter | 0.670 | 0.048 | 1.0E-05 |
| PELI1 | pellino homolog 1 (Drosophila) | protein binding, ubiquitin-protein ligase activity | 1.754 | 0.020 | 1.1E-05 |
| TMCC2 | transmembrane and coiled-coil domain family 2 | protein binding | 0.490 | 0.013 | 6.9E-06 |
| LRRC3 | leucine rich repeat containing 3 | protein binding | 1.671 | 0.030 | 2.7E-05 |
| DHX32 | DEAH (Asp-Glu-Ala-His) box polypeptide 32 | helicase activity, ATP binding | 0.601 | 0.049 | 5.7E-05 |
| IVD | isovaleryl-CoA dehydrogenase | metabolic pathway | 0.643 | 0.043 | 2.4E-05 |
| ZFHX2 | zinc finger homeobox 2 | transcription | 0.606 | 0.022 | 4.4E-05 |
| PDK2 | pyruvate dehydrogenase kinase, isozyme 2 | metabolic pathway | 0.482 | 0.023 | 4.4E-05 |
| RBBP4 | retinoblastoma binding protein 4 | protein binding, histone binding | 0.758 | 0.044 | 2.3E-06 |
| VAT1 | vesicle amine transport protein 1 homolog (T. californica) | transporter | 0.568 | 0.029 | 2.9E-05 |
| CACNA1D | calcium channel, voltage-dependent, L type, alpha 1D subunit | ion channel activity | 0.705 | 0.046 | 3.9E-05 |
| TTLL1 | tubulin tyrosine ligase-like family, member 1 | cilium function | 0.492 | 0.012 | 8.2E-05 |
| ANKMY1 | ankyrin repeat and MYND domain containing 1 | protein binding, metal ion binding | 0.491 | 0.047 | 3.7E-04 |
Differentially expressed genes between asthma and non-asthma groups at baseline and also significantly responsive to RV-A16 infection.
| Gene Symbol | Gene name | Biological function | Baseline difference P-value | Viral infection correlation p-value |
|---|---|---|---|---|
| BBS1 | Bardet-Biedl syndrome 1 | Acetylation, cilia assembly | 0.0022 | 2.7E-08 |
| LGALS9 | lectin, galactoside-binding, soluble, 9 | Cell adhesion | 0.0043 | 7.1E-11 |
| BAZ1A | bromodomain adjacent to zinc finger domain, 1A | Transciption | 0.0087 | 4.6E-08 |
| CX3CL1 | chemokine (C-X3-C motif) ligand 1 | Chemokine | 0.0087 | 3.5E-09 |
| KIAA0232 | KIAA0232 | Unknown | 0.0087 | 5.5E-08 |
| SAP30 | Sin3A-associated protein, 30kDa | Transciption | 0.0087 | 5.6E-08 |
| APOBEC4 | apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 4 (putative) | mRNA editing | 0.0152 | 3.1E-06 |
| BTN3A3 | butyrophilin, subfamily 3, member A3 | T cell mediated immunity | 0.0152 | 1.5E-07 |
| CCDC30 | coiled-coil domain containing 30 | Unknown | 0.0152 | 7.4E-05 |
| FAM81A | family with sequence similarity 81, member A | Unknown | 0.0152 | 2.7E-06 |
| IFI30 | interferon, gamma-inducible protein 30 | Superoxide anion generation | 0.0152 | 1.7E-09 |
| KIAA0319 | KIAA0319 | Cell adhesion | 0.0152 | 1.2E-05 |
| KLC4 | kinesin light chain 4 | Microtubule motor activity | 0.0152 | 1.0E-06 |
| MARCKSL1 | MARCKS-like 1 | Actin binding | 0.0152 | 4.6E-08 |
| NEK1 | NIMA (never in mitosis gene a)-related kinase 1 | Cilium assembly | 0.0152 | 3.9E-06 |
| PRSS12 | protease, serine, 12 (neurotrypsin, motopsin) | Zymogen activation, exocytosis | 0.0152 | 2.2E-07 |
| RAPGEF5 | Rap guanine nucleotide exchange factor (GEF) 5 | Small GTPase mediated signal transduction | 0.0152 | 1.8E-08 |
| WDR52 | WD repeat domain 52 | Unknown | 0.0152 | 1.8E-05 |
| WRB | tryptophan rich basic protein | Unknown | 0.0152 | 3.1E-08 |
| C1orf88 | chromosome 1 open reading frame 88 | Cell projection organization | 0.0260 | 2.2E-08 |
| CDHR3 | cadherin-related family member 3 | Homophilic cell adhesion | 0.0260 | 1.6E-04 |
| CHKA | choline kinase alpha | Lipid metabolic process | 0.0260 | 2.4E-06 |
| CLOCK | clock homolog (mouse) | Transciption | 0.0260 | 5.9E-07 |
| DAB2IP | DAB2 interacting protein | Negative regulation of cell migration | 0.0260 | 6.2E-08 |
| DNAH12 | dynein, axonemal, heavy chain 12 | Microtubule motor activity | 0.0260 | 2.4E-05 |
| ENDOD1 | endonuclease domain containing 1 | Unknown | 0.0260 | 1.3E-11 |
| EPB41L4B | erythrocyte membrane protein band 4.1 like 4B | Actomyosin structure organization | 0.0260 | 3.8E-06 |
| GNL3L | guanine nucleotide binding protein-like 3 (nucleolar)-like | GTP catabolic process; ribosome biogenesis | 0.0260 | 2.0E-06 |
| HIST2H2BE | histone cluster 2, H2be | Nucleosome assembly | 0.0260 | 2.5E-05 |
| KIAA1377 | KIAA1377 | Unknown | 0.0260 | 9.7E-06 |
| LRRC6 | leucine rich repeat containing 6 | cilium movement | 0.0260 | 3.2E-04 |
| NRG2 | neuregulin 2 | Signal transduction | 0.0260 | 5.5E-05 |
| PCM1 | pericentriolar material 1 | Cilium assembly | 0.0260 | 5.4E-07 |
| SPATA6 | spermatogenesis associated 6 | Cell differentiation | 0.0260 | 9.9E-07 |
| SPICE1 | spindle and centriole associated protein 1 | Cell division | 0.0260 | 6.9E-08 |
| TCP11L2 | t-complex 11 (mouse)-like 2 | Cell morphogenesis | 0.0260 | 1.3E-06 |
| TMEM67 | transmembrane protein 67 | Cilium assembly | 0.0260 | 6.1E-07 |
| C5AR1 | complement component 5a receptor 1 | Epithelial cell proliferation | 0.0260 | 6.4E-08 |
| CERKL | ceramide kinase-like | Negative regulation of cell Apoptosis | 0.0411 | 3.9E-06 |
| CNNM3 | cyclin M3 | Ion transport | 0.0411 | 5.2E-07 |
| DNAH6 | dynein, axonemal, heavy chain 6 | Microtubule-based movement | 0.0411 | 4.0E-05 |
| DNAL1 | dynein, axonemal, light chain 1 | Cilium function | 0.0411 | 4.9E-07 |
| ENKUR | enkurin, TRPC channel interacting protein | Cilium function | 0.0411 | 8.0E-06 |
| GPR85 | G protein-coupled receptor 85 | Signal transduction | 0.0411 | 1.8E-09 |
| IFITM1 | interferon induced transmembrane protein 1 (9–27) | Negative regulation of viral genome replication | 0.0411 | 1.9E-10 |
| KIF2A | kinesin heavy chain member 2A | Microtubule-based movement | 0.0411 | 5.8E-09 |
| LOC157381 | hypothetical LOC157381 | Unknown | 0.0411 | 2.2E-06 |
| LOC646851 | similar to OTTHUMP00000028720 | T cell proliferation | 0.0411 | 2.0E-05 |
| RABGAP1L | RAB GTPase activating protein 1-like | Regulation of protein organization | 0.0411 | 2.0E-05 |
| RABL5 | RAB, member RAS oncogene family-like 5 | Small GTPase mediated signal transduction | 0.0411 | 4.0E-07 |
| SYBU | syntabulin (syntaxin-interacting) | Unknown | 0.0411 | 2.4E-08 |
| PSMB9 | proteasome (prosome, macropain) subunit, beta type, 9 (large multifunctional peptidase 2) | Cell cycle | 0.0450 | 5.7E-07 |
Fig 5Expression of secreted cytokines/chemokines in culture medium.
16/42 cytokines tested had robust expression levels and were significantly up-regulated at 24 hr after RV-A16 infection across 12 donors (p value<0.05). Differences were not significant between asthma and non-asthma groups (p>0.05). Red lines represent asthma samples, blue lines represent non-asthma samples. Each line represents the mean and standard deviation of log2 concentration of each cytokine/chemokine.
Fig 6MUC5AC expression is upregulated in response to HRV infection.
A) Immunofluorescence of MUC5AC in ALI cultures from donors 21 (non-asthma, non-smoker), 23 (non-asthma, smoker), 26 (asthma, non-smoker) and 11(asthma, smoker) show an increase in staining with HRV treatment, with only donor 23 having high baseline expression. Green: MUC5AC, blue: DAPI staining for nuclei, representative images, scale bar: 50 μm. N = 6 ALI cultures per group (asthma and non-asthma). B and C) Quantification of immunofluorescence staining presented as either dot plot (B) or box plot (C). Positively stained area was measured and presented as % of total epithelial area. Red dots indicate outliers (> 1.5x inter-quartile distance). B) Inclusion of all data from 6 non-asthmatic and 6 asthmatic donors in analysis. C) Removal of non-diseased smokers (donors 11 and 23) from the data set results in significant differences between HRV and vehicle treated tissues in both non-asthmatic and asthmatic donors as determined by ANOVA and Tukey HSD test.